Cardiac Troponins and Heart Failure (carTn-HF) (DSB.AD006.239)

Area tematica

Scienze biomediche

Area progettuale

Struttura responsabile del progetto di ricerca

Istituto di fisiologia clinica (IFC)

Responsabile di progetto

CHIARA CASELLI
Telefono: 050 3153229
E-mail: chiara.caselli@ifc.cnr.it

Abstract

This study could provide insights into the molecular changes that occur in cardiac tissue in both HF pediatric and adult patients. It is unclear if these mechanisms are the cause or the effect of the failing heart, but they could represent a possible future therapeutic targets (Movassagh M, et al 2011; Sabia C, et al 2017). In particular, the deregulation in the expression of specific miRNAs associated to myocardial dysfunction led to develop research for the application of antagomir-based therapy in the patients with HF (van Rooij E and Kauppinen S 2014). Thus, results from this study could allow to assess whether these molecules can be useful for diagnosis and prognosis in the current clinical setting for patients with HF, also addressing for a personalized management and a targeted therapy.

Obiettivi

This study could provide insights into the molecular changes that occur in cardiac tissue in both HF pediatric and adult patients. It is unclear if these mechanisms are the cause or the effect of the failing heart, but they could represent a possible future therapeutic targets (Movassagh M, et al 2011; Sabia C, et al 2017). In particular, the deregulation in the expression of specific miRNAs associated to myocardial dysfunction led to develop research for the application of antagomir-based therapy in the patients with HF (van Rooij E and Kauppinen S 2014). Thus, results from this study could allow to assess whether these molecules can be useful for diagnosis and prognosis in the current clinical setting for patients with HF, also addressing for a personalized management and a targeted therapy.

Data inizio attività

01/01/2019

Parole chiave

heart failure

Ultimo aggiornamento: 25/06/2025